CANbridge Pharmaceuticals Inc. (1228.HK)

HKD 0.16

(0.65%)

Market Cap (In HKD)

65.84 Million

Revenue (In HKD)

102.87 Million

Net Income (In HKD)

-378.83 Million

Avg. Volume

22.19 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.112-1.1
PE
-
EPS
-
Beta Value
-0.521
ISIN
KYG1821D1097
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James Qun Xue M.B.A., Ph.D.
Employee Count
-
Website
https://www.canbridgepharma.com
Ipo Date
2021-12-10
Details
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.